Danish Pharma Hopes Stand-alone Medicines Agency Will Speed Up Drug Reviews
This article was originally published in The Pink Sheet Daily
Pharma group hopes DMA will clear up drug review backlog once it is separated from larger health authority.
You may also be interested in...
Major organizational changes are in store for the Danish Medicines Agency in the New Year that will aim to modernize its processes and functioning.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.